A Double-Blind, Multi-Centre, Active-Controlled (15, 30, and 45 mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar (0.5 and 1 mg) in Patients With Type 2 Diabetes Mellitus (GALLEX 6)
A Double-Blind, Multi-Centre, Active-Controlled (15, 30, and 45 mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar (0.5 and 1 mg) in Patients With Type 2 Diabetes Mellitus (GALLEX 6)
This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
Inclusion Criteria:
Exclusion Criteria:
Witchita, Kansas, United States
Ciudad de Buenos Aires, Argentina
Córdoba - Córdoba, Argentina
Salta - Salta, Argentina
Guadalajara, Jalisco., Mexico
Nuevo León, Monterrey, Mexico
Puebla, Mexico, Mexico
Co Antrim N Ireland, United Kingdom
Mid Glamorgan, United Kingdom
Pembrokeshire, United Kingdom
Surrey, United Kingdom
Wiltshire, United Kingdom